Isomorphic Labs – a company using frontier AI for drug design and development – is the latest to receive investment from Sovereign AI.

- Isomorphic Labs – a company using frontier AI for drug design and development – is the latest to receive investment from Sovereign AI.
- Investment forms part of a raise by London-based scale-up as Britain’s AI sector continues to accelerate.
- Isomorphic Labs is founded by AI pioneer Sir Demis Hassabis, whose breakthroughs have been honoured with accolades including the Nobel Prize and Breakthrough Prize.
Isomorphic Labs, a London-founded and headquartered company, using AI to design and develop new medicines, has been named as the latest firm to receive investment from the


















